The Neuromuscular Disease Network for Canada

funder-logos_nmd4c

Lawrence Korngut

lawrence-korngut

Adult Neuromuscular Neurologist; Director, Calgary Neuromuscular Program

Associate Professor, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary

Email Lawrence

Read more about Lawrence

Biography

Dr Lawrence Korngut is a neurologist, clinical neurophysiologist and Director of the Calgary Neuromuscular Program and the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He is the National Principal Investigator of the Canadian Neuromuscular Disease Registry that now includes 31 participating clinics and over the past ten years has recruited over 4400 patients.

Dr Korngut is the former Chair of the Canadian Neuromuscular Diseases Network (CAN-NMD), which was funded by the Canadian Institutes of Health Research and Muscular Dystrophy Canada in 2014 and consists of a nationwide collaboration of researchers, clinicians, and allied health professionals aiming to improve the lives those affected by neuromuscular conditions through improving clinical care, research capacity and education. He is the former Chair of the Medical and Scientific Advisory Committee and served on the Board of Directors of Muscular Dystrophy Canada.

Dr Korngut completed his undergraduate degree in Life Sciences at Queen’s University (Kingston, Canada), medical school and neurology residency at Western University (London, Canada), neuromuscular clinical and research fellowship and Masters of Science in Clinical Epidemiology at the University of Calgary, Alberta, Canada. He serves as the Director of Innovation and Commercialization at the Hotchkiss Brain Institute.

Within NMD4C Dr Korngut will bring in his experience of Canadian networking in CAN-NMD and participates in the network’s work in trial capacity building.

Recent publications

Shefner, JM, Andrews, JA, Genge, A, Jackson, C, Lechtzin, N, Miller, TM et al.. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2020. 1-13 PMID:32969758

Hodgkinson, V, Lounsberry, J, M'Dahoma, S, Russell, A, Benstead, T, Brais, B et al.. The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Through a Nationwide, Pan-Neuromuscular Disease Registry. J Neuromuscul Dis. 2020. PMID:32925088

Bharti, K, Khan, M, Beaulieu, C, Graham, SJ, Briemberg, H, Frayne, R et al.. Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study. Neuroimage Clin. 2020.28 102385 PMID:32871387

Hodgkinson, VL, Chapman, K, Izenberg, A, Lochmüller, H, O'Connell, C, O'Ferrall, EK et al.. Response to provincial governments' decisions regarding monitoring for adults with Spinal Muscular Atrophy. Can J Neurol Sci. 2020. 1-10 PMID:32713403

Kalra, S, Müller, HP, Ishaque, A, Zinman, L, Korngut, L, Genge, A et al.. A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS. Neurology. 2020.95 (8)e943-e952 PMID:32646955

See more on PubMed